Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Epizyme, Inc. Appoints Jason P. Rhodes President



               Epizyme, Inc. Appoints Jason P. Rhodes President

PR Newswire

CAMBRIDGE, Mass., July 3, 2013

CAMBRIDGE, Mass., July 3, 2013 /PRNewswire/ -- Epizyme, Inc., (NASDAQ: EPZM) a
clinical stage biopharmaceutical company creating innovative personalized
therapeutics for patients with genetically defined cancers, announced today
that Jason P. Rhodes, Executive Vice President and Chief Financial Officer,
has been named President of Epizyme. Mr. Rhodes, who was previously Executive
Vice President and Chief Financial Officer, will continue to be Chief
Financial Officer and report to Robert J. Gould, Ph.D., Chief Executive
Officer.

"Jason joined Epizyme in March 2010 and has been instrumental in our growth
and success," said Dr. Gould. "He has served as Chief Business Officer and
Chief Financial Officer during his tenure and has been a key partner for me in
building the business and charting our strategic course. I am pleased to
recognize his many contributions with this promotion. I look forward to
Jason's continued growth and leadership as part of our executive team at
Epizyme."

Prior to joining Epizyme, from July 2007 to March 2010, Mr. Rhodes served as
Vice President, Business Development at Alnylam Pharmaceuticals, Inc. (NASDAQ:
ALNY) where he drove the establishment and management of several key strategic
alliances and contributed to the growth of the business in many ways. Prior to
Alnylam, he was a founder and partner with Fidelity Biosciences, Fidelity
Investments' biopharma venture capital group. Mr. Rhodes received a B.A. from
Yale University and an M.B.A. from the Wharton School of the University of
Pennsylvania.

"On behalf of the Board of Directors, I congratulate Jason on his appointment
as President," said David Mott, Lead Independent Director of Epizyme. "The
strong partnership between Robert and Jason has helped the impressive
leadership team and Epizyme as an organization build a unique company with
world class science, outstanding business execution, and an innovative and
dynamic strategy. Most importantly, we believe that we are on the cusp of
translating our success to date into a family of important new therapeutics
for patients with genetically defined cancers. We look forward to Jason's
continued contributions to our growth and success and to improving the lives
of cancer patients and their families."

"I am grateful for this recognition and honored to be a part of the strong
leadership team at Epizyme," said Epizyme's new President, Jason P. Rhodes. "I
look forward to continuing to collaborate with Robert and the entire Epizyme
team to build value for shareholders and to deliver innovative new
therapeutics to cancer patients."

About Epizyme, Inc.

Epizyme, Inc. is a clinical stage biopharmaceutical company creating
personalized therapeutics for patients with genetically defined cancers.
Epizyme has built a proprietary product platform that the company uses to
create small molecule inhibitors of a 96-member class of enzymes known as
histone methyltransferases, or HMTs. HMTs are part of the system of gene
regulation, referred to as epigenetics, that controls gene expression. Genetic
alterations can result in changes to the activity of HMTs, making them
oncogenic (cancer-causing). By focusing on the genetic drivers of cancers,
Epizyme's targeted science seeks to match the right medicines with the right
patients for a personalized approach to cancer treatment.

For more information, visit http://www.epizyme.com and connect with us on
Twitter at @EpizymeRx.

SOURCE Epizyme, Inc.

Website: http://www.epizyme.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement